Literature DB >> 15806160

Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.

Brent W Sutherland1, Jill Kucab, Joyce Wu, Cathy Lee, Maggie C U Cheang, Erika Yorida, Dmitry Turbin, Shoukat Dedhar, Colleen Nelson, Michael Pollak, H Leighton Grimes, Kathy Miller, Sunil Badve, David Huntsman, C Blake-Gilks, Min Chen, Catherine J Pallen, Sandra E Dunn.   

Abstract

Akt/PKB is a serine/threonine kinase that promotes tumor cell growth by phosphorylating transcription factors and cell cycle proteins. There is particular interest in finding tumor-specific substrates for Akt to understand how this protein functions in cancer and to provide new avenues for therapeutic targeting. Our laboratory sought to identify novel Akt substrates that are expressed in breast cancer. In this study, we determined that activated Akt is positively correlated with the protein expression of the transcription/translation factor Y-box binding protein-1 (YB-1) in primary breast cancer by screening tumor tissue microarrays. We therefore questioned whether Akt and YB-1 might be functionally linked. Herein, we illustrate that activated Akt binds to and phosphorylates the YB-1 cold shock domain at Ser102. We then addressed the functional significance of disrupting Ser102 by mutating it to Ala102. Following the stable expression of Flag:YB-1 and Flag:YB-1 (Ala102) in MCF-7 cells, we observed that disruption of the Akt phosphorylation site on YB-1 suppressed tumor cell growth in soft agar and in monolayer. This correlated with an inhibition of nuclear translocation by the YB-1(Ala102) mutant. In conclusion, YB-1 is a new Akt substrate and disruption of this specific site inhibits tumor cell growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15806160     DOI: 10.1038/sj.onc.1208590

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  103 in total

1.  AUF-1 and YB-1 are critical determinants of β-globin mRNA expression in erythroid cells.

Authors:  Sebastiaan van Zalen; Grace R Jeschke; Elizabeth O Hexner; J Eric Russell
Journal:  Blood       Date:  2011-12-01       Impact factor: 22.113

2.  The kinases IKBKE and TBK1 regulate MYC-dependent survival pathways through YB-1 in AML and are targets for therapy.

Authors:  Suhu Liu; Anna E Marneth; Gabriela Alexe; Sarah R Walker; Helen I Gandler; Darwin Q Ye; Katherine Labella; Radhika Mathur; Patricia A Toniolo; Michelle Tillgren; Prafulla C Gokhale; David Barbie; Ann Mullally; Kimberly Stegmaier; David A Frank
Journal:  Blood Adv       Date:  2018-12-11

3.  Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance.

Authors:  Karen To; Abbas Fotovati; Kristen M Reipas; Jennifer H Law; Kaiji Hu; Jing Wang; Arezoo Astanehe; Alastair H Davies; Lawrence Lee; Anna L Stratford; Afshin Raouf; Pauline Johnson; Isabelle M Berquin; Hans-Dieter Royer; Connie J Eaves; Sandra E Dunn
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

4.  Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species.

Authors:  Valentina Evdokimova; Peter Ruzanov; Michael S Anglesio; Alexey V Sorokin; Lev P Ovchinnikov; Jonathan Buckley; Timothy J Triche; Nahum Sonenberg; Poul H B Sorensen
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

5.  YB-1 transcription in the postnatal brain is regulated by a bHLH transcription factor Math2 through an E-box sequence in the 5'-UTR of the gene.

Authors:  Sachiyo Ohashi; Reiko Fukumura; Takashi Higuchi; Shunsuke Kobayashi
Journal:  Mol Cell Biochem       Date:  2009-02-19       Impact factor: 3.396

6.  Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha.

Authors:  Harish Srinivas; Dianren Xia; Nicole L Moore; Ivan P Uray; Heetae Kim; Long Ma; Nancy L Weigel; Powel H Brown; Jonathan M Kurie
Journal:  Biochem J       Date:  2006-05-01       Impact factor: 3.857

7.  Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells.

Authors:  Sandhya Pande; Gillian Browne; Srivatsan Padmanabhan; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

8.  Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.

Authors:  Anna L Stratford; Christopher J Fry; Curtis Desilets; Alastair H Davies; Yong Y Cho; Yvonne Li; Zigang Dong; Isabelle M Berquin; Philippe P Roux; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-11-27       Impact factor: 6.466

9.  Data perturbation independent diagnosis and validation of breast cancer subtypes using clustering and patterns.

Authors:  G Alexe; G S Dalgin; R Ramaswamy; C Delisi; G Bhanot
Journal:  Cancer Inform       Date:  2007-02-19

10.  Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Authors:  Golareh Habibi; Samuel Leung; Jennifer H Law; Karen Gelmon; Hamid Masoudi; Dmitry Turbin; Michael Pollak; Torsten O Nielsen; David Huntsman; Sandra E Dunn
Journal:  Breast Cancer Res       Date:  2008-10-16       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.